NanoKTN Helps Pharmidex Find New Facility
Stevenage Bioscience Catalyst, the UK’s First Open Innovation (OI) Bioscience Campus, is New Home for Pharmidex
The Nanotechnology Knowledge Transfer Network (NanoKTN – ww.nanoktn.com), one of the UK’s primary knowledge-based networks for Micro and Nanotechnologies, is pleased to announce that it has helped one of its members secure new facilities at the Stevenage Bioscience Catalyst, the UK’s first open innovation bioscience campus, pioneering a unique culture to drive early stage biotech, pharma and medtech developments.
Stevenage Bioscience Catalyst (SBC) offers state-of-the-art facilities that are pre-fitted and ready-for-science. In keeping with the project’s open innovation ethos, the lay-out of the campus is designed to encourage cooperation, dialogue and interaction between tenant companies and also with scientists on the GlaxoSmithKline R&D site.
An initial introduction was made by the NanoKTN at the NanoKTN’s NanoMed mission in 2011on behalf of Pharmidex to Dr Martino Picardo, CEO of Stevenage Bioscience Catalyst. Following this introduction, Pharmidex secured facilities in the Catalyst’s Bio-Incubator Building for 2013.
Mo Alavijeh, CEO at Pharmidex comments, “We attended the NanoKTN’s NanoMed mission in 2011 and discussed with NanoKTN staff our specialist requirement of bioscience laboratories for the company. Having successfully grown the company, we found ourselves running out of lab space at our old premises. The NanoKTN recommended the SBC and set up a meeting which resulted in Pharmidex moving into their new facilities at SBC. The new laboratory at SBC is perfect for our needs. Not only does it offer state-of-the-art facilities, but also an exciting environment surrounded by similar innovative companies for potential collaboration.”
Dr Martino Picardo, CEO of Stevenage Bioscience Catalyst, said “We’re delighted to welcome Pharmidex to the biosciences hub at Stevenage Bioscience Catalyst. The yare a very welcome addition to our vibrant bioscience community. Stevenage Bioscience Catalyst campus has been designed to foster collaboration and interaction between tenant companies with the hope that the combination of opportunity and cooperation will breed innovation and commercial success. We hope that Pharmidex’s new laboratories will deliver further success for the company.”
Pharmidex is unique in providing bespoke integrated assessments of ADMET-PK/PD profiles of drug candidates for major pharma, biotechs, academics and medical charities worldwide, thus speeding up their identification of compounds with the best chance of becoming new medicines. Founded in the UK in 2002, Pharmidex solutions draw on the company’s world-leading expertise in the area of CNS and oncology medicines research and its openness to collaborating with compatible organisations.
For further information about the NanoKTN, please visit www.nanoktn.com or email enquiries@nanoktn.com.
Established by the Technology Strategy Board, the NanoKTN is managed by Centre for Process Innovation Ltd, a leading technology development and consulting company.
ENDS
About NanoKTN:
The NanoKTN facilitates the transfer of knowledge and experience between industry and research, offering companies dealing in small-scale technology access to information on new processes, patents and funding as well as keeping up-to-date with industry regulation. The four broad areas that the NanoKTN focuses on are: Promoting and facilitating knowledge exchange, supporting the growth of UK capabilities, raising awareness of Nanotechnology, and providing thought leadership and input to UK policy and strategy.
About The Technology Strategy Board:
The Technology Strategy Board is a business-led government body which works to create economic growth by ensuring that the UK is a global leader in innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org.
About Stevenage Bioscience Catalyst:
Stevenage Bioscience Catalyst is the UK’s first open innovation bioscience campus, pioneering a unique culture to drive early stage bioscience technology and company development, and building a thriving community. It is backed by £38m of funding from its founding partners – GlaxoSmithKline, the Wellcome Trust, the Department for Business, Innovation and Skills, the Technology Strategy Board and the former East of England Development Agency.
Consisting of an Incubator, an Accelerator and a Hub, covering 60,000 sq ft of laboratory, office and networking space, the independent facility houses a range of companies, from virtual and start-up firms to those which are more established, as well as other organisations. Located on the GlaxoSmithKline Stevenage site, Stevenage Bioscience Catalyst is in the unique position of operating in proximity to the expertise and resources of a major pharmaceutical company, close to both London and Cambridge. For more information, please go to www.stevenagecatalyst.com
About Pharmidex:
Pharmidex is unique in providing bespoke integrated assessments of ADMET-PK/PD profiles of drug candidates for major pharma, biotechs, academics and medical charities worldwide, thus speeding up their identification of compounds with the best chance of becoming new medicines. Founded in the UK in 2002, Pharmidex solutions draw on the company’s world-leading expertise in the area of CNS and oncology medicines research and its openness to collaborating with compatible organisations.
Pharmidex is a bio and pharmaceutical service provider with extensive expertise in CNS drug discovery and ADMET/PK. Founded in the UK in 2002,Pharmidex provides high quality experimental preclinical ADMET/PK data, critical to the progression of drug discovery programmes and research collaborations. Through extensive knowledge of drug discovery and development, Pharmidex has been able to deliver a high level of customer satisfaction and forge several strategic international alliances, focussing on operations in the following areas: in vitro ADMET, in-vivo Pharmacology, CNS Drug Discovery, Bioanalysis, Metabolite Identification, Bioimaging, and Zebrafish. Pharmidex also has extensive experience in research collaborations with a number of successful on going and completed projects.
About Knowledge Transfer Networks (KTNs):
KTNs https://ktn.innovateuk.org/web/guest/networks have been set up by government, industry and academia to facilitate the transfer of knowledge and experience between industry and the science base. They bring together diverse organisations and provide activities and initiatives that promote the exchange of knowledge and the stimulation of innovation in these communities.
The first KTNs were set up in 2005 and the network continues to grow. They are active in sectors, technologies and market-based areas and they interact strongly with the government’s Technology Programme and overall technology strategy.
About CPI:
The Centre for Process Innovation (CPI) is a UK based technology innovation centre and part of the government’s High Value Manufacturing Catapult. CPI offers market and technology expertise along with cutting-edge development assets to help its public and private sector clients build and prototype the next generation of products, processes and services quickly and efficiently, and with minimal risk. CPI has the capability to develop products and processes for companies working in the pharma, chemical, energy, transportation and printable electronics markets. Cutting-edge facilities are manned by commercially experienced scientists and engineers, and are equipped with development laboratories, prototyping facilities and pilot plants that enable clients to prove and scale up processes from the laboratory stage through to commercial reality. CPI also offers a multi-disciplined team who work together on project management, investment and market opportunities to ensure each business fulfils its potential.
Editorial Contacts
Fiona Brewer/Graham Thatcher
MCC International
T: 023 8011 1977
F: 023 8011 1978
